Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...

As tariffs loom, 3M spinoff Solventum’s operating margins are continuing to shrink, and its investors are looking toward the company’s announced purification business sale for balance sheet relief.

Solventum (NYSE:SOLV) yesterday announced fourth-quarter results that came in ahead of the consensus forecast on Wall Street.

The addition of Solventum’s business provides a strategic fit with Thermo Fisher and will create value for customers, according to Marc N. Casper, chairman, president, and CEO of Thermo Fisher.

Piper Sandler raised the firm’s price target on Solventum (SOLV) to $84 from $75 and keeps a Neutral rating on the shares. The firm notes ...

Wells Fargo raised the firm’s price target on Solventum (SOLV) to $75 from $73 and keeps an Equal Weight rating on the shares. The Q4 beat was ...

Solventum Corp (SOLV) reports robust earnings per share and strategic advancements, while navigating separation complexities and market headwinds.

Minnesota-based Solventum is one of the largest providers of sterilization devices, wound dressings, medical tape and other hospital consumables used by healthcare facilities. More than half of its ...

ST. PAUL, Minn. - Solventum Corporation (NYSE: SOLV) reported fourth-quarter earnings that fell short of analyst expectations, sending shares down 2% in after-hours trading. The healthcare technology ...